The presentations will be made by Dr Tanios Bekaii-Saab from the Mayo Clinic, the co-inventor of the KEY-Vaxx and B-Vaxx cancer vaccines along with Imugene scientific advisor Professor Pravin Kaumaya.
Content from the presentations remains embargoed until the start of the conference and will be made available online after the annual meeting begins.
The first abstract presentation is entitled ‘Development of a novel PD-1 vaccine and in combination with two Chimeric HER-2 peptide vaccine provides synergistic inhibition of tumour growth in a syngeneic Balc/c model challenged with CT26/HER-2 carcinoma cell line’.
The second is called ‘A phase-one active immunotherapy with a combination of two Chimeric (Trastuzumab-like and Pertuzumab-like) human epiderman growth factor receptor 2 (HER-2) B cell peptide vaccine emulsified in ISA 720 and Nor-MDP adjuvant in patients with advanced solid tumours
Imugene’s KEY-Vaxx is a B-cell peptide cancer vaccine designed to treat tumours such as lung cancer by interfering with PD-1/PD-L1 binding and interaction.
It is also designed to produce an anti-cancer effect similar to Keytrude, Opdivo and the other immune checkpoint inhibitor monoclonal antibodies that are transforming cancer treatment.
KEY-Vaxx when combined with B-Vaxx has shown great potential in pre-clinical studies, demonstrating robust PD-1 and HER-2 antibody responses in all vaccinated mice.
This indicates that the combined vaccination is effective in reducing tumour growth in a Balc/c syngeneic model of colon carcinoma versus either the PD-1 vaccine alone or more important the positive control gold standard that is anti-mouse PD-1 monoclonal antibody.
The vaccine combination was found to be safe and did not appear to exhibit toxicity or autoimmunity.
B-Vaxx is a proprietary B-cell peptide cancer vaccine being developed that targets multiple oncology indications.
The phase-one B-Vaxx trial studied the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumours.
The open-label, dose escalation study evaluated B-Vaxx in patients with solid tumours that over-express the HER-2/neu receptor.
B-Vaxx has been shown to stimulate a potent polyclonal antibody response to HER-2/nue, a well-established and validated cancer target.
A phase-two study evaluating the activity of B-Vaxx in patient over-expressing HER-2/nue is being conducted at clinical institutions in the US.